Publication date: May 13, 2019
This post was originally published on this site Aubagio taken as 14 milligram (mg) tablet once daily significantly reduces the risk of relapse in people with relapsing multiple sclerosis (MS) over time irrespective of their prior treatment history, a pooled analysis of Phase 2 and Phase 3 trial results show. These studies enrolled relapsing MS patients, categorized into subgroups depending on whether they had a prior treatment (and type of treatment): those who were treatment-nacEFve (no treatment for two years before joining the trial); those recently treated with Aubagio at 7 mg (core studies started some patients at 7 mg before moving them to 14 mg in extension trials); and those recently treated with another disease-modifying therapy (DMT), further subdivided into patients who discontinued that DMT within 6 months prior to enrolling in an Aubagio study, and those who stopped using a different DMT between six months and two years before. In this pooled post-hoc analysis of all Aubagio trials, researchers evaluated the long-term efficacy and safety of its use in patients categorized by type of prior MS treatment (including those who were using no treatment in the two years prior to an Aubagio study’s start and were classified as treatment naive). The pooled analysis included 1,695 patients treated with Aubagio at 14 mg daily, of whom 1,021 had been treatment nacEFve, 353 had taken Aubagio at 7 mg, 158 had used another DMT within six months of a study’s start (called a baseline measure), and 163 patients who had stopped another DMT in the longer time group. These findings show that Aubagio at 14 mg effectively lowers disability in the long-term in relapsing MS patients, irrespective of their prior treatment preferences, the researchers concluded.
|drug||DRUGBANK||Antithymocyte immunoglobulin (rabbit)|
- #AANAM – RRMS Patients Switching to Lemtrada Report Greater Satisfaction with Treatment and Improvements in Quality of Life
- Emerging oral immunomodulating agents – focus on teriflunomide for the treatment of multiple sclerosis.